NEW YORK (360Dx) – Many resource-limited regions suffer from high rates of hepatitis B virus infections, and chronic liver infection with HBV can lead to cirrhosis and liver cancer. Traditional HBV testing, requiring costly PCR-based assays and biopsies, is often too expensive for these regions, but new research suggests a potential $20 blood test could be used to determine if a person is a good candidate for antiviral treatment for the virus.
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.